NeuMoDx Molecular Revenue and Competitors

Claim your profile

Detroit, MI USA



Total Funding

Estimated Revenue & Valuation

  • NeuMoDx Molecular's estimated annual revenue is currently $22.1M per year.(i)
  • NeuMoDx Molecular received $20.0M in venture funding in May 2016.
  • 0
  • NeuMoDx Molecular's total funding is $66M.

Employee Data

Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





NeuMoDx Molecular News

2022-04-20 - QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q1 2022 Results - Earnings Call Transcript

Sales trends for QIAstat-Dx and NeuMoDx systems were in line with our full ... well balanced between life science and molecular diagnostics,...

2022-04-17 - Qiagen Q1 Revenues Rise on Strong MDx Sales, Surpassing ...

The firm's molecular diagnostic revenues were up 28 percent year over year to ... and sales for NeuMoDx dropped 15 percent to $27 million,...

2019-09-05 - Global Biochips Market Overview 2019: Market Value ... Lab-on-a-chip and Molecular Biology ... Cancer Therapy; QIAGEN NV Selects NeuMoDx Molecular, Inc for CE-IVD Assays Purchase ...

2019-08-12 - NeuMoDx Files Defense, Counterclaims in BD Patent ...

NEW YORK – NeuMoDx has filed a response with the District of ... by Becton Dickinson that the molecular diagnostics developer infringed on ...

2019-06-20 - BD sues NeuMoDx over patents for diagnostic device

Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2009 for $275 million. HandyLab was developing bench-top ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

NeuMoDx Molecular Funding

DateAmountRoundLead InvestorsReference
2014-04-02$21.0MBPfizer VenturesArticle